The showcase aimed to demonstrate that Czechia has evolved into a systematic and reliable source of European biotech dealflow. With a sector now comprising 393 active companies and generating €3 billion in annual turnover, the region is seeking to secure its place in Europe’s late-stage capital flows.
“This is a story of a country that has already shaped the global HIV market once, and whose research pipeline continues to produce globally relevant science,” said Milan Prášil, Director of IOCB Tech. He emphasised that the nation's excellent scientific base now offers significant new opportunities for international research collaborations on urgent health issues.
The event also served as a preview for BioEquity Europe 2026, which will be hosted in Prague for the first time in its history—a milestone signalling that Central Europe is now a structural part of the European biotech map.
Complementing the professional programme, the showcase featured a cultural perspective on the region's scientific heritage with a performance of The Elegance of the Molecule by the Dejvice Theatre, depicting the story of Prof. Antonín Holý’s life-saving antiviral discoveries.